PROSTATE CANCER

This study tests a new type of focused radiation (SBRT) to treat early-stage prostate cancer that hasn't spread. The goal is to destroy only the tumor, not the whole prostate, which may reduce side effects like incontinence and impotence. About 42 men will receive two painless ra…

This study tests a new way to treat prostate cancer using MRI-guided radiation that targets only the tumor, not the whole prostate. For early-stage patients, a single high-dose session may be enough to cure the cancer. For higher-risk patients, the focused dose is followed by sta…

This study tests whether adding immunotherapy (pembrolizumab) and a PARP inhibitor (olaparib) to standard radiation can better control high-risk prostate cancer. About 64 men with localized but aggressive prostate cancer will receive the combination. The goal is to see if this ap…

This study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The goal is to find a safe dose and see if it can shrink tumors. About 216 adults with tumors that have sp…

This program provides access to an experimental drug called AVM0703 for people with various solid tumors or blood cancers who have not responded to other treatments. It is available in the US upon a doctor's request. So far, 37 patients have received the drug, and side effects ha…

This study tests whether blocking nerve signals to the prostate can slow or stop the spread of high-risk prostate cancer. About 21 men with aggressive prostate cancer will receive one or two injections of a nerve-blocking agent before their scheduled prostate removal surgery. Res…

This study tests whether a highly focused type of radiation (SBRT) can better manage prostate cancer that returns after the prostate is removed, compared to usual treatments. About 284 men with a rising PSA after surgery will be randomly assigned to receive SBRT or standard care.…

This early-phase study tests a new drug, BG-68501, in people with advanced solid tumors (like breast, ovarian, lung, or stomach cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors when used alone or with other…

This study tests whether adding a DNA vaccine (pTVG-AR) and/or an immunotherapy drug to standard hormone therapy can help eliminate high-risk prostate cancer before surgery. About 60 men with newly diagnosed, high-risk prostate cancer who are scheduled for prostate removal will p…

This study looks at whether men with low-volume, hormone-sensitive prostate cancer that has spread can safely stop taking certain drugs (apalutamide or enzalutamide) after 12 months, instead of continuing them indefinitely. The goal is to reduce side effects and costs. If the can…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This study tests whether two common, low-cost drugs—aspirin and atorvastatin (a cholesterol-lowering statin)—can help men with a type of advanced prostate cancer live longer. About 1,210 men whose cancer has stopped responding to hormone therapy will take one or both drugs alongs…

This study tests a new way to give radiation for men with unfavorable or high-risk prostate cancer. It combines two types of radiation: external beams aimed at the pelvis and a short internal implant (brachytherapy) placed directly into the tumor. The main goal is to see how well…

This study looks at whether a special heart scan (CCTA) can help doctors better manage heart disease risk in prostate cancer patients who are on or about to start hormone therapy. About 100 participants will either get the scan or standard care. The goal is to see if the scan fin…

This study tests whether a personalized physical activity program, combined with support from a trained peer (another prostate cancer patient) and a doctor's prescription, can help inactive prostate cancer patients become and stay more active. The goal is to improve long-term hea…

This early-phase study tests a new drug called AGX101 in people with advanced solid tumors that have not responded to standard treatments. AGX101 is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find the safest dose and to check for sid…

This study tests two drugs, saruparib and darolutamide, given alone or together before prostate removal surgery in men with newly diagnosed, localized prostate cancer. The goal is to see how these drugs affect cancer cells and to check their safety. About 120 men will take part.

This study tests a new medicine called ifinatamab deruxtecan (I-DXd) against standard chemotherapy (docetaxel) in people with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. The goal is …

This early-stage study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells and boost the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatments.…

This study tests a new drug called SHR-4394 combined with other cancer treatments for men with prostate cancer. The goal is to find a safe dose and see if it lowers PSA levels, a marker of cancer activity. About 100 men aged 18 to 85 with advanced prostate cancer will take part. …

This study tests a new way to give radiation for prostate cancer. Instead of treating the whole prostate, doctors will focus the radiation only on the tumor. The goal is to see if this reduces side effects like bladder and bowel problems. The study involves 150 men with intermedi…

This study looks at the long-term safety of the drug enzalutamide in people with prostate cancer who are already benefiting from it in an earlier study. About 900 participants will continue their treatment and be monitored for side effects. The goal is to gather more safety infor…

This study looks at whether eating a controlled Mediterranean-style diet for a short time before prostate cancer surgery can lower insulin levels and improve other health measures. About 20 men scheduled for prostate removal will take part. Researchers will check blood and tissue…

This study tests a shorter course of proton therapy to the whole pelvis, followed by a high-dose internal radiation boost (brachytherapy), for men with high-risk or unfavorable intermediate-risk prostate cancer. The goal is to see if this approach is safe and does not cause sever…

This study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have tried at least one prior therapy. The main goals are to find a safe dose and check for early signs of tumor shrinkage. About 27 adults will…

This study tests whether adding the drug relacorilant to standard hormone therapy and enzalutamide can better shrink high-risk prostate cancer before surgery. About 90 men with advanced, localized prostate cancer that hasn't spread will take the drug combination or a placebo for …

This study tests whether adding a new drug (SHR-1701) to targeted radiation (SBRT) can slow down advanced prostate cancer that no longer responds to hormone therapy. About 66 men aged 18-80 with metastatic castration-resistant prostate cancer will take part. The main goal is to s…

This study is for men with prostate cancer that has spread to pelvic lymph nodes visible only on a special PET scan. It compares standard hormone therapy plus radiation to a stronger combination that includes abiraterone and prednisone. The goal is to see if the stronger treatmen…

This study tests a nerve grafting surgery to help men who have had erectile dysfunction for over 18 months after prostate cancer surgery. The procedure connects healthy nerves to the damaged ones to try to restore natural erections. One hundred men will be followed for a year to …

This early-phase study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find the safest dose and check for side effects. Researchers will also watch for any signs that the dru…

This study follows 100 men with prostate cancer who choose to have high-intensity focused ultrasound (HIFU) as their treatment. The goal is to see how well the procedure destroys cancer tissue and how it affects quality of life, including urinary, bowel, and sexual health. Partic…

This study tests whether adding precise, high-dose radiation to each metastatic lesion (SABR MDT) alongside standard hormone therapy and prostate radiation can improve outcomes for men whose prostate cancer has spread to a few spots (oligometastatic). About 122 men with 1-5 asymp…

This early-phase study tests TJ101, an experimental antibody-drug conjugate, in 200 adults with advanced solid tumors (lung, prostate, esophageal, and others) who have no standard options left. The main goals are to find a safe dose and check for early signs of tumor shrinkage. P…

This study tests a new pill called HRS-5041 combined with other cancer treatments for men with advanced prostate cancer that has spread or stopped responding to standard therapy. About 100 men aged 18-80 will participate to find the best dose and see if the combo can shrink tumor…

This study tests a new drug called AZD9750, alone or with another drug (saruparib), in people whose prostate cancer has spread to other parts of the body and is no longer controlled by standard treatments. The goal is to find the safest dose and see if it can shrink tumors or low…

This early-phase trial tests a new drug called MDX2001 in about 285 adults with advanced solid tumors (cancers that have spread). The main goals are to check the drug's safety and find the right dose. Researchers will also see if it shrinks tumors. This is not a cure, but it may …

This study tests whether taking curcumin (a compound found in turmeric) after prostate removal surgery can help keep prostate cancer from returning. About 650 men who had their prostate removed for cancer will take curcumin or a placebo. The main goal is to see if curcumin lowers…

This study tests whether using a special PET scan (PSMA-PET) to guide radiation can reduce side effects while still controlling prostate cancer that has returned after surgery. About 54 men will receive a lower dose of radiation to the pelvis plus a higher dose to the exact spots…

This study tests a new way to give radiation to men whose prostate cancer has returned after surgery. Using a special scan (PSMA PET) to find exactly where the cancer is, doctors will give higher radiation doses to those spots and lower doses to healthy areas. The goal is to bett…

This study tests whether adding a short course of the oral hormone drug Relugolix to targeted radiation (SBRT) works better than radiation alone for men with unfavorable intermediate-risk prostate cancer. About 60 men will be randomly assigned to one of the two treatments. The go…

This study tests a new two-drug combination (gedatolisib plus darolutamide) in men with metastatic castration-resistant prostate cancer (mCRPC) — a form of prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest and most …

This study tests whether a 12-week exercise program can reduce the number of cancer cells in the blood of men with advanced prostate cancer. Twenty men on hormone therapy will exercise regularly and have their blood tested before, during, and after the program. The goal is to see…

This study looks at whether taking creatine supplements while doing supervised resistance training for 12 weeks can help men with prostate cancer who are on hormone therapy (ADT) maintain or improve muscle mass, strength, and physical function. ADT often causes muscle loss and we…

This study looks at how well proton radiation (and sometimes hormone therapy) works for prostate cancer that has come back or is at high risk of coming back after surgery. About 70 men whose cancer has not spread will receive this treatment. The goal is to control the cancer whil…

This study tests a targeted freezing treatment (cryotherapy) for men with intermediate-risk prostate cancer. Instead of treating the whole prostate, doctors freeze only the area with cancer, aiming to control the disease while reducing side effects. The trial involves 30 men and …

This study tests whether taking a targeted drug (olaparib) plus hormone therapy for 6 months before prostate removal surgery can eliminate or greatly reduce cancer in men with high-risk prostate cancer and specific gene changes. About 32 men will take the drugs, then have surgery…

This study compares two types of radiation therapy for men with low- or intermediate-risk prostate cancer: SBRT (a precise, high-dose external beam treatment) and LDR brachytherapy (implanting tiny radioactive seeds). The goal is to see which causes fewer urinary and bowel side e…

This study tests whether adding omeprazole (a common heartburn medicine) to standard chemotherapy can help shrink tumors or slow cancer growth in men with advanced prostate cancer that has stopped responding to other treatments. About 50 men will receive either cabazitaxel or doc…

This study compares two treatments for men with intermediate-risk prostate cancer: a focused ultrasound (HIFU) that targets only the tumor, versus complete surgical removal of the prostate. The goal is to see which approach offers better value for money and quality of life. About…

This study tests a new way to deliver radiation for prostate cancer that hasn't spread. Instead of the usual 5 sessions, doctors will give 3 high-dose sessions to see if it causes fewer bladder and bowel side effects. About 175 men with early-stage prostate cancer will take part.…

This study tests a new way to choose prostate cancer treatment. Instead of treating the whole prostate, doctors will use genetic tests to decide if a patient can have focal therapy—which targets only the cancer—or needs more aggressive treatment like surgery or radiation. The goa…

This early-phase study tests whether combining a targeted radiation drug (177Lu-PSMA-617) with liver-directed therapy is safe for men with metastatic castration-resistant prostate cancer that has spread to the liver. About 30 participants will receive the combination to check for…

This study tests whether a shorter, more intense radiation schedule (5 sessions instead of 20) with a higher dose to the main tumor can better control intermediate- or high-risk prostate cancer. About 484 men will be randomly assigned to one of the two treatments. The goal is to …

This study tests whether giving the drug enoblituzumab for 12 weeks before prostate removal surgery can help prevent cancer from coming back in men with high-risk localized prostate cancer. About 219 men will be randomly assigned to receive either enoblituzumab or standard care. …

This study tests a new drug (HRS-1167) combined with two standard treatments (abiraterone and prednisone) in 66 men with metastatic prostate cancer. The goal is to find the safest dose and see if the combination helps control the cancer. Participants must have confirmed prostate …

This study tests a new injectable radioactive drug, Actinium-225 rhPSMA-10.1, in 60 men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug aims to find and destroy cancer cells with radiation. Researchers will check safety and tu…

This study tests a precise MRI-guided radiation approach for men with low- or intermediate-risk prostate cancer. The treatment targets the tumor while avoiding areas important for erections, aiming to reduce the risk of erectile dysfunction. Seventy men will receive five high-dos…

This study tests a new drug called 177Lu-rhPSMA-10.1 in men with metastatic castrate-resistant prostate cancer, a type of prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells. The study has two phases: Pha…

This study for veterans with prostate cancer that has returned in a few spots (1-10) tests whether adding PET-directed local therapy to standard hormone therapy can delay the cancer from becoming resistant to treatment. About 464 participants will be randomly assigned to standard…

This study compares a shorter, high-dose radiation method (SBRT) to the usual longer radiation plus a radioactive seed implant (brachytherapy) for men with unfavorable-risk prostate cancer. The goal is to see if the faster approach works just as well at controlling the cancer. Ab…

This study compares a newer, nerve-sparing prostate surgery to the standard approach. The goal is to see if the newer method controls cancer just as well while improving urinary function and reducing complications like penile shortening and hernias. About 600 men scheduled for pr…

This study tests a procedure called irreversible electroporation (IRE) using the NanoKnife system to treat intermediate-risk prostate cancer. The goal is to destroy cancer cells with fewer side effects than standard treatments like surgery or radiation. About 100 men over age 50 …

This study looks at whether proton therapy can safely treat tumors that have returned after previous radiation. Unlike standard X-ray radiation, proton beams are more targeted and may spare healthy tissue. The trial will enroll 1,800 adults with various cancers to see if this app…

This study tests whether simvastatin, a common cholesterol medication, can help the immune system better attack prostate cancer. Men with localized prostate cancer who are scheduled for surgery will take simvastatin for 8 weeks before their operation. Researchers will compare the…

This study is testing whether a single, very high dose of precisely targeted radiation can safely control intermediate-risk prostate cancer. About 200 men will receive one 24 Gray dose to the whole prostate, with some getting an extra boost to the main tumor. The goal is to reduc…

This study tests a new drug, ADI-PEG20, combined with two chemotherapy drugs (carboplatin and cabazitaxel) in men with an aggressive form of prostate cancer that is hard to treat. The goal is to find the safest dose and see if the combination can control the disease. About 30 men…

This study tests whether adding an immune-boosting treatment (Sipuleucel-T) to ongoing hormone therapy can better control metastatic prostate cancer that has started to progress. About 26 men with asymptomatic or mildly symptomatic cancer will be randomly assigned to receive Sipu…

This study tests a new type of radiation therapy for men with intermediate-risk prostate cancer. Using MRI guidance, doctors give a higher radiation dose to the main tumor while lowering the dose to the rest of the prostate. The goal is to improve tumor control and reduce side ef…

This early-stage study tests a new drug called DXC014 in people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goal is to check safety and find the right dose. About 150 participants will take part in this first-in-human tria…

This study tests a treatment called bipolar androgen therapy (BAT) in men with a type of prostate cancer that has stopped responding to standard hormone therapy but hasn't spread yet. The goal is to see if BAT can delay the cancer from spreading to other parts of the body. About …

This study tests an experimental drug called ACE-86225106 in adults with advanced solid tumors (like ovarian, breast, or prostate cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tu…

This study tests a new drug (AAA817) that delivers radiation directly to prostate cancer cells, combined with standard hormone therapy, in men with advanced prostate cancer that no longer responds to hormone treatment alone. About 940 adults will be randomly assigned to receive e…

This study tests a new drug called pocenbrodib, either alone or with other treatments, in people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to find the safest dose and see if it can shrink tumors or lower PSA levels. A…

This early-phase study tests a new drug, CLSP-1025, designed to direct immune cells to attack tumors that have a specific p53 R175H mutation. The trial enrolls adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have worsened after standard treatments.…

This study tests a new drug, APL-5125, in about 100 adults with advanced solid tumors like colorectal, pancreatic, and breast cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The trial has two pha…

This study will follow 300 men with early-stage prostate cancer who choose to have high-intensity focused ultrasound (HIFU) treatment. The goal is to track how well the treatment controls cancer and what side effects occur, especially regarding urinary and sexual function. Resear…

This study tests a new drug called saruparib added to standard radiation and hormone therapy for men with high-risk prostate cancer that has a BRCA gene mutation. The goal is to see if it can delay the cancer from spreading to other parts of the body. About 700 men will participa…

This study is for men with a certain type of prostate cancer that is at higher risk of coming back. It compares two treatments: standard care (6 months of hormone therapy plus focused radiation) versus the same radiation alone. The goal is to see if skipping hormone therapy still…

This study is for men whose prostate cancer has come back after surgery, shown by rising PSA levels. It compares a standard few weeks of radiation to a much shorter course of just a few days. The goal is to see if the shorter option works just as well to control the cancer while …

This study tests an herbal supplement called INM176 in 45 men with prostate cancer whose PSA levels are rising after prior treatment or who are on active surveillance. The goal is to find a safe dose and see if the supplement can stabilize or lower PSA levels over six months. Par…

This early-stage study tests a new drug, JANX007, in men with metastatic castration-resistant prostate cancer that has worsened after other treatments. The main goals are to check safety and find the right dose. About 272 participants will receive the drug to see if it can help c…

This study is for people with a certain type of prostate cancer that is not too advanced but has some higher-risk features. It tests whether adding a short course of the drug darolutamide to standard radiation therapy can better control the cancer. The main goal is to see if this…

This study tests a new way to treat prostate cancer using heat from ultrasound waves guided by MRI. About 21 adults with early-stage prostate cancer will get the procedure, where a small device is placed in the urethra to heat and destroy cancer cells. The goal is to see if this …

This study is for people with a certain type of prostate cancer that is more likely to come back. The researchers want to see if a precise, high-dose radiation treatment called SBRT can control the cancer without needing hormone therapy. They will also use a special test called D…

This study tests a new drug called INR102 in people with a specific type of advanced prostate cancer (PSMA-positive) that has spread and stopped responding to hormone therapy. The goal is to see if the drug is safe, how it moves through the body, and whether it can shrink tumors …

This study compares two treatments for men with intermediate-risk prostate cancer that hasn't spread: proton beam radiation alone versus radiation plus hormone-blocking therapy (androgen suppression). About 192 men will receive either 28 sessions of proton therapy or the same rad…

This study compares two radiation therapy schedules for men with localized prostate cancer. One uses fewer, stronger doses (ultra-hypofractionated) and the other uses slightly more, moderate doses. Both are combined with a brachytherapy boost. The goal is to see which approach ca…

This study tests a precise radiation therapy for men with high-risk prostate cancer. It uses advanced imaging (PSMA PET/MR) to guide the radiation beam directly to the tumor, including any small spread. The goal is to improve the chance of keeping cancer from coming back after tr…

This study tests a new injectable drug, ASP5541, for men with advanced prostate cancer that has spread. The drug is a different form of the standard treatment abiraterone, given as a shot every 12 weeks instead of daily pills. The study will compare how well the injection works a…

This study is for men with prostate cancer that has spread to 1-3 small spots in the body (oligometastatic). It compares standard radiation alone to radiation followed by a targeted radioactive drug called Lu-PSMA. The goal is to see if the combination can keep the cancer from gr…

This program provides early access to two investigational immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers such as colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who hav…

This study tests a combination of two advanced radiation techniques for men with high-risk or advanced prostate cancer. The goal is to see if this approach is safe and effective at controlling the cancer while reducing side effects. Participants will receive treatment over about …

This study tests whether adding an injected drug (PDS01ADC) to a daily pill (enzalutamide) can better control prostate cancer that has returned after initial treatment. About 65 men will receive either enzalutamide alone or both drugs for 3 months, with possible extra treatment. …

This study tests two experimental drugs (HS-20093 or SHR2554) taken with standard hormone therapy in men with metastatic prostate cancer. The goal is to see if these combinations can lower PSA levels and control the cancer. About 218 men aged 18 to 80 with advanced disease will p…

This early-stage study tests a new drug, JANX014, in 43 men with a hard-to-treat type of prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. The main goals are to check the drug's safety and find the right dose, while also looking …

This early-stage study tests a new drug called ASP5541 in about 12 Chinese men whose prostate cancer has spread. The drug is given as a shot in the hip, along with standard treatments (prednisone and hormone therapy). The main goals are to check the drug's safety and how it moves…

This study looks at how well the drug T-DXd works in adults with advanced HER2-positive cancers that have spread and no longer respond to other treatments. About 100 people will take part, and researchers will track whether tumors shrink and how long the benefit lasts. The goal i…

This study tests whether adding an experimental drug called tinengotinib to standard hormone therapy (abiraterone or enzalutamide) is safe and effective for men with metastatic castration-resistant prostate cancer (mCRPC) — a type of prostate cancer that has spread and stopped re…

This study is for people with prostate cancer that has spread to nearby lymph nodes but not to distant organs. It compares two radiation strategies: one that boosts the prostate only, and one that boosts both the prostate and the affected lymph nodes. All participants also receiv…

This study tests whether giving a combination of hormone therapy, darolutamide, and pembrolizumab before prostate surgery, followed by pembrolizumab after surgery, can reduce or eliminate cancer in high-risk prostate cancer patients. About 40 men with aggressive, non-spread prost…

This study tests whether adding the experimental drug mevrometostat to the standard treatment enzalutamide can delay cancer growth better than enzalutamide alone in men with metastatic castration-sensitive prostate cancer. About 1,000 participants will be randomly assigned to rec…

This early-phase trial tests a new treatment called A-CAR032 for men with a tough-to-treat type of advanced prostate cancer that has stopped responding to standard hormone therapy. The study aims to see if the treatment is safe and to get an early look at whether it can shrink tu…

This study tests a new way to treat advanced prostate cancer that has stopped responding to standard hormone therapy. About 50 men with no pain from their cancer will receive a sequence of two drug combinations: first, a high dose of testosterone with another drug, then a differe…

This study is testing whether adding a focused ultrasound treatment to standard hormone therapy and chemotherapy can better control advanced prostate cancer that has spread to other parts of the body. The trial will enroll 116 men with high-tumor-burden metastatic hormone-sensiti…

This study tests a precise type of radiation therapy guided by MRI (MR-linac) for men with prostate cancer that hasn't spread widely. The goal is to see if this approach is well-tolerated, reduces side effects, and improves quality of life. About 50 participants will receive targ…

This trial provides a single patient with advanced prostate cancer access to an experimental treatment called X-PACT, which combines a light-sensitive drug (methoxsalen) with X-rays to kill tumor cells and possibly trigger an immune response. The patient has no other standard tre…

This early-stage study tests a new drug called OCT-598 in about 51 adults with advanced solid tumors (breast, lung, prostate, head/neck, or stomach cancer). The main goals are to check safety, find the best dose, and see how the drug works alone or with standard treatments. Parti…

This study tests how well a short course of hormone therapy (ADT) shrinks high-risk prostate cancer before surgery. About 50 men will get ADT, then have PSMA PET scans to see if the cancer shrinks. The goal is to see if this approach can improve outcomes after prostate removal.

This study tests whether a 16-week exercise program designed for Black men with prostate cancer can lower their risk of heart disease. Participants are on hormone therapy (ADT), which can increase heart risks. The program includes aerobic and resistance exercises, and the study w…

This study tests whether intensive cholesterol-lowering therapy can increase immune cells (CD8+ T cells) in the prostate of men with prostate cancer who are on active surveillance. About 140 participants will take a combination cholesterol drug (Vytorin or ezetimibe) for 3-6 mont…

This study looks at how well ablative therapies (treatments that destroy cancer cells using heat or cold) work for men with localized prostate cancer. Researchers will track cancer control, side effects, and quality of life in 225 men receiving these treatments for the first time…

This study looks at whether treating small numbers of cancer spread (1 to 10 spots) right away helps people live longer compared to waiting six months. It includes adults with lung, colorectal, or prostate cancer that has newly spread. The goal is to see if immediate treatment im…

This study is testing a new type of radiation therapy called SMART, which uses MRI scans to guide treatment in real time. It includes up to 397 adults with various cancers like pancreas, lung, or prostate cancer. The goal is to see if this approach is safe and improves tumor cont…

This early-phase study tests a new drug, QXL138AM, for safety and tolerability in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. Participants must have tried standard treatments without success. The study will also look…

This early-phase study tests whether a diabetes medication called dapagliflozin is safe and tolerable when taken for four weeks before prostate removal surgery in men with localized prostate cancer. The study involves 24 participants with intermediate- to high-risk prostate cance…

This study tests whether a short, focused radiation treatment called SBRT can safely boost the effectiveness of standard radiation for prostate cancer, without using needles. About 150 men with unfavorable localized prostate cancer will receive this boost. Researchers will track …

This study looks at whether metformin, a common diabetes drug, can help prostate cancer patients who have high blood sugar or are overweight. About 100 men will either get metformin plus lifestyle tips or just lifestyle tips. The goal is to see if this approach is practical and i…

This early-stage study tests a new drug called AMG 509, alone or with other medications, in people with a type of advanced prostate cancer that no longer responds to hormone therapy. The main goals are to check safety and how the drug moves through the body. About 479 participant…

This study tests a new treatment for prostate cancer that hasn't spread. It uses a special drug activated by light to destroy cancer cells. About 43 men will take part. The goal is to see if it's safe and effective, with follow-up over 18 months.

This study tests whether adding a targeted radiation drug (225Ac-J591) to standard immunotherapy (pembrolizumab) and hormone therapy works better for men with advanced prostate cancer that has spread and stopped responding to treatment. About 52 men will participate. The goal is …

This study tests a new drug called AAA817 in adults with a specific type of advanced prostate cancer (PSMA-positive) that has stopped responding to standard treatments like hormone therapy, chemotherapy, and a targeted radiation therapy. About 443 participants will be randomly as…

This study looks at men whose prostate cancer has come back after surgery, with new spots found on only one side of the pelvis using a special scan (PSMA PET). The goal is to see if removing lymph nodes only on that one side works as well as removing them on both sides, while cau…

This early-stage trial tests a new drug (REGN5678) plus an existing immunotherapy (cemiplimab) in men with metastatic castration-resistant prostate cancer that has worsened after at least two prior treatments. The goal is to find the best dose that balances safety and effectivene…

This study tests whether adding the drug talazoparib to standard hormone therapy and enzalutamide can help shrink prostate cancer that has spread to nearby lymph nodes. About 30 men will receive the combination before having their prostate removed. The main goal is to check safet…

This study is testing if giving a higher dose of radiation directly to the prostate (called HDR brachytherapy) can better control early-stage prostate cancer without causing more side effects. About 36 men with low- or favorable intermediate-risk prostate cancer will receive one …

This study tests if axelopran, a drug typically used for opioid-induced constipation, can help control tumor growth in people with advanced breast, lung, pancreas, or prostate cancer. About 34 adults whose cancer has worsened after standard treatment will take axelopran daily for…

This study tests a new drug called 225Ac-LNC1011 for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells using a special targeting molecule. The goal is to find the safest and most effective …

This study tests whether men with metastatic hormone-sensitive prostate cancer can safely take breaks from hormone therapy after an initial treatment period. About 1,600 participants who have already responded well to therapy will be randomly assigned to either continue treatment…

This study tests a new way to deliver internal radiation (brachytherapy) for men with early-stage prostate cancer. By using a special PET scan to find only the aggressive parts of the tumor, doctors hope to treat just those areas and leave healthy tissue alone, which may reduce s…

This study tests a drug called REGN5678 in men with high-risk prostate cancer who are scheduled for prostate removal surgery. The goal is to check the drug's safety and how it affects the cancer before surgery. About 42 men will take part. This is an early-phase trial, so the mai…

This study tests whether a new treatment called irreversible electroporation (IRE), which uses electrical pulses to destroy cancer cells, works as well as the standard radiation boost for men with intermediate-risk prostate cancer. About 224 participants will receive standard ste…

This study is testing whether a personalized diet and exercise program is practical for men with metastatic prostate cancer who are already receiving hormone therapy. Researchers will enroll 30 participants to see how many stick with the program. The goal is to understand if life…

This early-phase trial is testing a new way to deliver radiation for low-to-intermediate risk prostate cancer. Instead of many sessions, it uses just two high-dose treatments, with an extra boost to the main tumor. The goal is to see if this approach is safe and feasible for abou…

This study tests a precise, high-dose radiation treatment (SBRT) combined with the diabetes drug metformin for men whose prostate cancer has come back in the same area after previous radiation. The goal is to find the safest and most effective radiation dose. About 44 men who had…

This study compares two modern treatments for men with low-to-intermediate risk prostate cancer that hasn't spread: a robotic partial prostatectomy (removing part of the prostate through a single port) and high-intensity focused ultrasound (HIFU, which uses sound waves to destroy…

This study tests whether adding lymph node radiation to standard salvage radiotherapy helps men whose prostate cancer has returned after prostate removal. About 374 men with low but rising PSA levels will be randomly assigned to receive either standard radiation or a personalized…

This study is testing an experimental drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow their…

This study tests whether combining two drugs—pembrolizumab (an immunotherapy) and 177Lu-PSMA-617 (a targeted radiation therapy)—can slow the growth of advanced prostate cancer that has stopped responding to hormone treatments. About 48 men with metastatic castration-resistant pro…

This early-stage trial tests a new drug called STM-416p, given directly into the prostate area during surgery to remove the prostate in men with prostate cancer. The main goal is to check the drug's safety and find the best dose. About 18 men with intermediate to high-risk prosta…

This study tests whether a single, precise dose of radiation can safely control prostate cancer in men with intermediate or high-risk disease. About 58 participants will receive one targeted treatment session, along with standard hormone therapy. The goal is to see if this shorte…

This study tests a natural compound from licorice root (glycyrrhizin) in 60 men with prostate cancer who are scheduled for surgery. Participants take the extract daily before their operation to see if it lowers PSA levels and is safe. The goal is to learn if this supplement can h…

This study tests whether adding the drug homoharringtonine to standard hormone therapy before prostate removal can improve outcomes for men with high-risk or advanced prostate cancer. About 93 participants will receive the combination before surgery. The goal is to see if this ap…

This study tests an experimental drug called AZD6621 for men with metastatic prostate cancer that has spread. The drug is designed to help the immune system attack cancer cells. The trial has two parts: first, finding the safest dose, then testing that dose in more people to see …

This study tests a new approach for men with a tough-to-treat form of prostate cancer that has spread and stopped responding to standard hormone therapy. Instead of continuing hormone blockers, participants get a precise type of radiation to all visible tumors plus a radioactive …

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The drug targets a protein called HER3 found on some cancer cells. About 740 adults with various cancers like lung, breast, or melanoma w…

This study tests whether eating 2 ounces of walnuts daily for 4-10 weeks can slow prostate cancer growth in 50 men who are scheduled for prostate removal surgery. Participants are randomly assigned to either add walnuts to their usual diet or continue their normal diet. The main …

This study is testing whether using MRI scans to guide radiation can lower the dose to healthy parts of the prostate while giving a higher dose to cancer spots. The goal is to reduce bowel-related side effects and preserve quality of life. About 60 men with intermediate- or high-…

This study looks at whether giving radiation therapy to areas where prostate cancer has spread (called metastasis-directed radiotherapy) can help control the disease better than the usual treatment. About 200 men with newly diagnosed prostate cancer that has spread will receive h…

This early-stage study tests a new drug called BL-M14D1 in people with advanced small cell lung cancer or other neuroendocrine cancers that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 120 adults will take part, a…

This study tests a new medicine called PRL-02 depot, given as a shot into the muscle every 12 weeks, to lower testosterone in men with advanced prostate cancer. The goal is to find a safe dose and see if it works alone or with another drug, enzalutamide. About 174 men whose cance…

This study tests whether advanced scans (PSMA PET/CT) and a genetic test (Decipher) can help doctors choose the right treatment for high-risk prostate cancer. For some patients, treatment may be intensified to better control the cancer; for others, it may be reduced to improve qu…

This study tests whether a new drug (BMS986365) combined with hormone therapy (degarelix) can safely shrink or eliminate high-risk prostate cancer before surgery. About 30 adults with localized high-risk prostate cancer will receive the drug combo for a few months, then have thei…

This early-stage study tests a new drug, DXC008, for safety and the right dose in people with prostate cancer or other solid tumors like Ewing sarcoma. About 110 adults who have not responded to standard treatments will take part. The goal is to see if the drug is safe and to get…

This study tests a new drug called 2141-V11 that helps the immune system find and kill prostate cancer cells. It is given as an injection directly into the tumor, either alone or with standard hormone therapy. The goal is to see if this approach can completely eliminate cancer or…

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This study tests the drug Enhertu in 60 men with a specific type of advanced prostate cancer (HER2-positive) that has stopped responding to standard hormone therapy and chemotherapy. The goal is to see if Enhertu can shrink tumors or slow the cancer's growth. Participants must ha…

This early-phase study tests a new radioactive drug called [225Ac]Ac-AKY-2519 in people with a hard-to-treat type of advanced prostate cancer (metastatic castration-resistant prostate cancer). The drug targets a protein (B7-H3) on cancer cells to deliver radiation directly to tum…

This study is for people with metastatic prostate cancer that has spread and is no longer controlled by hormone therapy. It tests a new drug called [212Pb]Pb-ADVC001, which delivers a precise dose of radiation directly to cancer cells. The goal is to find the safest and most effe…

This early-stage study tests two types of targeted radiation therapy (177Lu-PSMA-617 and 225Ac-PSMA-617) in 45 men with high-risk prostate cancer who are scheduled for prostate removal surgery. The goal is to see which therapy delivers more radiation to the tumor and how it affec…

This study tests a personalized approach to radiation therapy for men whose prostate cancer has returned after prostate removal surgery. Instead of giving everyone the same treatment, doctors will use PSA blood tests to decide who needs additional radiation and hormone therapy. T…

This study tests a new drug, FOG-001, in about 595 people with advanced solid tumors that have not responded to other treatments. The goal is to see if FOG-001 is safe and can shrink tumors or slow their growth. The trial focuses on several cancer types, including colorectal, pro…

This study tests a new drug called xaluritamig, given alone or with hormone therapy, before prostate removal surgery in men with intermediate or high-risk prostate cancer. The goal is to see if the drug is safe and if surgery afterward is still possible. About 40 men will take pa…

This study tests a personalized approach to treating prostate cancer in men who still have detectable PSA after prostate removal surgery. Participants receive radiation therapy plus the drug apalutamide, with the goal of reducing fatigue and other side effects compared to standar…

This study tests whether adding fasudil hydrochloride to immunotherapy can help control metastatic castration-resistant prostate cancer in patients who have already tried standard treatments. About 30 adults aged 18 to 85 will receive the combination therapy. Researchers will mea…

This study tests a new method called LaserSAFE that uses a special microscope to scan the removed prostate during surgery. The goal is to see if it can quickly find cancer at the edges of the prostate, helping surgeons decide whether to save or remove nearby nerves. About 693 men…

This study tests whether a special type of PET/CT scan (PSMA PET/CT) can more accurately find cancer that has spread to lymph nodes in men with intermediate- or high-risk prostate cancer. About 159 participants will receive the scan before their planned prostate removal surgery. …

This study aims to see if a new type of PET scan (68Ga-XACP3) can find prostate cancer tumors as well as or better than the current standard scan (68Ga-PSMA). About 60 adults with newly diagnosed, suspected recurrent, or treated prostate cancer will receive both scans. The result…

This study aims to see if a type of PET-CT scan (FCH-PET-CT) is better than standard scans (bone scan and MRI/CT) at finding cancer that has spread outside the pelvis in men with prostate cancer who have specific gene mutations (like BRCA). About 50 men with these mutations will …

This study is testing a new radioactive tracer called 18F-PSMA-1007 for PET/CT scans to see if it can better detect where prostate cancer has spread in the body. About 2800 adults who have already been treated for prostate cancer but have signs of possible recurrence will get the…

This early-stage study tests whether a special tracer made of tiny silica nanoparticles can safely help identify prostate cancer cells before and during surgery. The tracer is designed to attach to cancer cells and show up on both PET/MRI scans and a special camera used in the op…

This study looks at whether adding a special PET/CT scan (rhPSMA-7.3) to the usual MRI can find more aggressive prostate cancers in men who are currently just watching their low-risk cancer. About 120 men will get both scans before a confirmatory biopsy. The goal is to see if the…

This study is testing a special MRI scan that uses a substance called hyperpolarized pyruvate to make prostate cancer cells light up. The goal is to see if this scan can better detect advanced prostate cancer and show how well treatment is working. About 75 people with advanced p…

This study tests whether a special scan (PSMA PET/MRI) can better find aggressive prostate cancer in men whose standard MRI was negative but who still have a high suspicion of cancer. About 100 men will get both the new scan-guided biopsies and standard biopsies to compare detect…

This study is testing a special PET/CT scan that uses a radioactive tracer to find if prostate cancer has spread to nearby lymph nodes. It involves 380 men with newly diagnosed high-risk prostate cancer who are planning surgery. The goal is to see if this scan is more accurate th…

This study looks at whether a flexible MRI coil can accurately detect aggressive prostate cancers without needing a standard endorectal coil. About 258 men with intermediate- or high-risk prostate cancer will get an MRI before surgery. The goal is to see if this simpler MRI metho…

This study tests whether adding a special MRI scan to the standard prostate exam is safe and can collect useful data. About 75 men aged 40-90 with elevated PSA levels will get up to 15 extra minutes of scanning. Researchers will check for side effects and see if the new scan prod…

This study tests a custom device that uses electrical signals to detect if any prostate cancer tissue remains after the prostate is removed. About 200 men with prostate cancer having robotic surgery will take part. The goal is to help surgeons remove all cancer in one operation.

This study tests whether a new upright MRI machine can find prostate cancer as well as or better than current methods like the PSA blood test and standard MRI. About 550 men at risk for prostate cancer will get both types of MRI scans and answer questions about comfort. Researche…

This study compares two prostate biopsy techniques—cognitive-targeted and MRI-ultrasound fusion—to see which detects prostate cancer more accurately. About 80 men with suspicious MRI findings will participate. The results could help doctors choose the best method for diagnosing p…

This study is testing whether new types of MRI scans can more accurately find and grade prostate cancer without using contrast dye. About 300 men with suspected prostate cancer will get both standard and new MRI scans. The results will be checked against biopsy or surgery results…

This study is testing a new type of PET scan that targets a protein called Trop2, found on many solid tumors. The goal is to see if this scan can find and stage cancers like bladder, lung, liver, and ovarian cancer better than current methods. About 400 adults with confirmed or s…

This study tests a new approach for men with moderate risk of prostate cancer. Instead of an immediate biopsy, participants will be monitored with PSA tests and MRI scans over four years. The goal is to see if this strategy can safely avoid unnecessary biopsies and overdiagnosis …

This study tests whether combining two advanced scans (PSMA PET and MRI) is better than standard methods for finding prostate cancer in men with elevated PSA levels. About 204 men will get both scans and a biopsy to confirm results. The goal is to see if the combo scan reduces un…

This study aims to find out if prostate MRI is better than a panel of lab tests (like PSA) at detecting serious prostate cancer in men who have not yet been diagnosed. About 950 men scheduled for a biopsy will get both an MRI and lab tests. The goal is to see which method more ac…

This study compares two ways to use MRI images during a prostate biopsy: one uses computer software to fuse MRI and ultrasound images, the other relies on the doctor's visual estimation. The goal is to see which method finds more clinically significant prostate cancers. About 1,3…

This study is testing a special MRI technique that uses a substance called hyperpolarized pyruvate to see if it can better find high-grade prostate cancer (the more aggressive type). About 80 men scheduled for prostate removal surgery will get this scan. The goal is to see if thi…

This study tests a new type of PET scan (18F-DCFPyL-PSMA) to see how well it shows prostate cancer in 30 men with advanced disease who are already scheduled for a targeted radiation therapy. The goal is to compare this scan with the standard one to see if it detects cancer spots …

This study tests a robot-assisted ultrasound biopsy to improve how doctors take tissue samples from the prostate. About 483 men with elevated PSA or abnormal exams will be enrolled. The goal is to see if the robot helps find more aggressive cancers and reduces missed diagnoses co…

This study is testing whether special PET scans using radioactive tracers can better detect where prostate cancer has spread in the body. Researchers will compare these scans to standard imaging like CT and bone scans. The goal is to improve how doctors find cancer locations, not…

This study looks at whether a PSMA-PET scan can detect prostate cancer that comes back after focal treatment (a targeted therapy). About 70 men who had focal therapy for intermediate-risk prostate cancer will get a PSMA-PET scan one year later. The scan results will be compared t…

This study tests a new imaging agent called 68Ga-P16-093 against the standard 68Ga-PSMA-11 for detecting prostate cancer. Fifty men with untreated prostate cancer will receive both PET scans within a week. The goal is to see which agent finds more tumors and gives clearer images.

This study looks at whether a special type of scan called PSMA-PET CT can accurately rule out aggressive prostate cancer in men who are already on active surveillance (watchful waiting). Researchers will enroll 200 men with low or favorable intermediate-risk prostate cancer. Each…

This study is testing a new radioactive tracer called PSMA-T4 to see if it can safely and accurately find prostate cancer tumors during a special type of scan (SPECT/CT). About 80 adults with prostate cancer will receive the tracer and then have scans to compare with standard ima…

This study is testing a new computer software that creates risk maps from MRI scans to help doctors decide if a prostate biopsy is needed. About 180 people with known or suspected prostate cancer will have one MRI and one or two biopsies, and be followed for a year. The goal is t…

This study tests a new type of PET/CT scan using a radioactive tracer called copper Cu 64 PSMA I&T to see if it can accurately find prostate cancer that has spread to pelvic lymph nodes. About 439 men with newly diagnosed, high-risk prostate cancer who are planning to have their …

This study tests a new type of PET scan using a radioactive tracer called 64Cu-SAR-bisPSMA to see if it can better detect prostate cancer that has spread to nearby lymph nodes. About 383 men with high-risk prostate cancer who are scheduled for prostate removal surgery will get th…

This study is testing a new type of MRI scan to see if it can find prostate cancer more accurately than current methods. About 2000 men with suspected prostate cancer will get this special MRI, and the results will be checked against standard biopsies. The goal is to develop a be…

This study tests a new contrast agent called Gadopiclenol (Elucirem) to see if it improves MRI scans for finding aggressive prostate cancer. About 150 men scheduled for a prostate MRI with contrast will receive this agent. The goal is to see if it provides clearer images and bett…

This study is testing whether a special MRI scan (called biparametric MRI) can improve prostate cancer screening for men at high risk, such as Black men or those with a family history of prostate cancer. The study will enroll 100 men with low PSA levels (between 1.0 and 2.5) to s…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early and tell which type it is. In people with lung cancer, the test will also check for any cancer…

This study tests a new way to decide who needs a prostate biopsy. Instead of relying only on MRI, it adds a blood test called Prostate Health Index (PHI) to better tell which men have dangerous prostate cancer. The goal is to safely skip biopsies in men who don't need them, reduc…

This early-stage study tests a new imaging drug called Flotufolastat F-18 in 6 healthy Chinese adults. The drug is a radioactive tracer that helps spot prostate cancer cells on PET scans. The goal is to check its safety, how it spreads in the body, and the radiation dose received…

This early-stage study tests a new radioactive tracer called 68Ga-FC516 for PET/CT scans. It includes 10 participants—healthy adults and prostate cancer patients—to check safety, how the tracer spreads in the body, and how well it spots tumors compared to existing tracers. The go…

This study is testing whether a genetic test can better identify which men ages 55-69 are at high risk for serious prostate cancer and which men are at low risk. Current screening methods often lead to unnecessary biopsies for men who don't need them. The study will enroll 5,000 …

This study tests different ways to help Black or African American men aged 40 and older get screened for prostate cancer. Participants will receive either passive navigation, active navigation, or community-based screening to see which method works best. The goal is to increase t…

This study tests a device that uses mild electrical pulses to calm the nerves controlling the bladder. It aims to reduce urgent, frequent urination and improve quality of life in men with overactive bladder, including those with prostate issues or after prostate surgery. About 15…

This study tests whether adding local anesthesia during a prostate biopsy, while patients are already sedated, reduces pain after the procedure. Researchers will compare pain scores and recovery times between those who get the extra numbing and those who don't. About 800 men sche…

This study tests whether placing a special cord tissue graft (CLARIX® CORD 1K) during robotic prostate surgery helps men regain erections and bladder control faster. About 100 men with prostate cancer will be randomly assigned to get the graft or not. Researchers will track their…

This study looks at whether daily text message reminders to do pelvic floor exercises can help men recover bladder control faster after prostate surgery. About 132 men who are scheduled for prostate surgery will be split into two groups: one gets the text reminders, the other doe…

This study tests whether a special nurse-led education session and a direct referral to pelvic floor physiotherapy before prostate cancer surgery can reduce urine leakage afterward. About 80 men having prostate removal at Beaumont Hospital will be randomly assigned to either stan…

This study tests a 12-week home-based rehabilitation program for men with advanced prostate cancer living in rural areas. The program includes exercise and support to help manage side effects from hormone therapy and improve quality of life. Researchers want to see if this approa…

This pilot study tests if brodalumab, a drug approved for autoimmune diseases, can safely reduce severe side effects caused by cancer immunotherapy. About 11 adults with various solid tumors who have immune-related side effects will receive brodalumab. The goal is to see if it lo…

This study looks at men with prostate cancer who need radiation after their prostate is removed. It compares standard photon radiation with proton radiation to see which causes fewer bowel problems and improves quality of life. About 900 participants will be randomly assigned to …

This study looks at whether a new robotic surgery system that gives surgeons a sense of touch can help them learn the procedure faster and make it safer. Sixty men with localized prostate cancer will have their prostate removed by robot. The main goal is to see if the force feedb…

This study tests whether a telehealth exercise program can reduce cancer-related fatigue in rural breast and prostate cancer survivors. About 134 participants will either start the program right away or wait 12 weeks before beginning. They will do virtual fitness assessments, col…

This study tests a new care plan that uses technology to help doctors better manage the health of older adults (70+) who have cancer and other medical conditions. The goal is to see if this approach improves their quality of life over six months. About 720 people with breast, lun…

This study is for men with intermediate-risk prostate cancer who need radiation therapy. It compares the usual radiation dose to a lower dose, both given in just two sessions using a special MRI-guided machine. The main goal is to see if the lower dose causes fewer urinary side e…

This study tests whether a 16-week supervised exercise program (combining resistance, functional, and aerobic training) can improve frailty and muscle loss in 80 men with metastatic prostate cancer who are on hormone therapy. Participants must be pre-frail or frail. The goal is t…

This study tests a program called PC-PEP for men with prostate cancer. The program teaches life skills and healthy habits to improve mental health, fitness, and quality of life, and to reduce side effects from treatment. About 2130 men will take part. The goal is to help men feel…

This study tests a telemedicine program called FOCUS for people with advanced cancer. The program uses counseling techniques to help manage common symptoms like trouble sleeping, worry, tiredness, and low mood. Researchers will enroll 120 adults with advanced lung, breast, prosta…

This study tests a special radiation technique for prostate cancer that uses MRI scans to map and protect the nerves and blood vessels needed for erections. About 200 men will receive either this new approach or standard radiation. The goal is to see if the new method reduces sex…

This study looks at whether intermittent fasting (with an optional plant-rich diet) is practical for men with prostate cancer who are receiving hormone therapy. Researchers will track how many patients join, stay, and follow the diet. The goal is to see if this approach can impro…

This study looks at whether giving breast, prostate, and colorectal cancer survivors a personal referral to a tailored nutrition and exercise program helps them eat better and move more. About 306 survivors and healthcare providers will take part. The goal is to see if survivors …

This study tests a precise radiation technique for low- to intermediate-risk prostate cancer that avoids the urethra to lower the chance of urinary side effects. About 132 men will receive daily adaptive stereotactic body radiation therapy (SBRT) with urethral sparing. The goal i…

This study tests whether a digital support program can help people with breast, prostate, or colorectal cancer reduce the time they spend sitting during their treatment. The goal is to improve their well-being and lower future health risks. About 172 participants will be randomly…

This study compares two types of radiation therapy for prostate cancer: adaptive radiotherapy, which adjusts the treatment daily based on changes in the body, and conventional radiotherapy. The goal is to see if the adaptive approach causes fewer side effects like digestive or ur…

This study compares two different radiation schedules for men with low-risk prostate cancer: the standard five treatments versus a shorter course of just two treatments. The goal is to see if the shorter course can maintain sexual quality of life just as well, while still control…

This study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (ADT). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency, severity, and any liver…

This early-phase study tests whether tirzepatide, a weight-loss medication, can help overweight or obese men with intermediate-risk prostate cancer lose weight before their prostate removal surgery. The main goal is to see if the program is safe and feasible. About 30 men will ta…

This study tests whether 4-aminopyridine (4-AP) can speed up recovery from nerve damage that often happens during prostate cancer surgery. About 70 men aged 45-75 with early-stage prostate cancer will take either the drug or a placebo after their operation. The goal is to see if …

This study compares two radiation schedules for men whose prostate cancer has returned after surgery. One uses fewer, stronger doses (ultra-hypofractionated), the other uses standard moderate doses. The goal is to see which approach causes fewer bowel and urinary side effects two…

This study tests a new proton therapy technique called 'Spot Delete' for men with low- to intermediate-risk prostate cancer. The goal is to reduce bowel and bladder side effects by preventing proton beams from stopping in sensitive areas. The study will enroll 500 participants an…

This study tests whether adding acupuncture to standard anti-nausea medicine works better than medicine alone for people with nausea caused by chemotherapy. About 90 adults with breast, prostate, lung, gynecologic, colorectal, or metastatic pancreatic cancer will be split into tw…

This study tests whether using a virtual reality headset, an aromatherapy patch, or both can help men feel less pain, fear, and embarrassment during a prostate biopsy. About 208 men will be randomly assigned to one of four groups: VR only, aromatherapy only, both, or standard car…

This study tests whether a digital exercise program with virtual group sessions helps prostate cancer patients on hormone therapy stick to exercise guidelines. Hormone therapy can cause fatigue, weight gain, and muscle loss, but exercise can help. The trial will enroll 160 men an…

This study is testing whether lisinopril, a blood pressure medicine, can reduce urinary side effects in men receiving radiation for prostate cancer. About 30 men will take lisinopril during their radiation treatment, and researchers will track their urinary symptoms and lab resul…

This study is testing a mobile health app designed to help Black men who have had prostate cancer feel better and track their quality of life. About 248 men from diverse Black backgrounds will use the app and give feedback on how easy it is to use and how it affects their physica…

This study tests two different approaches to help men recover sexual function after prostate cancer surgery. It involves 224 men who had their prostate removed within the past 9 months. The goal is to see which method works better for improving erectile function.

This study tests a new way to give radiation for prostate cancer that uses MRI scans to adjust the dose to each patient's tumor. The goal is to reduce side effects while still controlling the cancer. About 20 men with intermediate-risk prostate cancer will receive 5 targeted radi…

This study tests whether placing ice inside the rectum before a prostate biopsy can lower pain, anxiety, stress hormone levels, and complications like bleeding. About 84 men having their first prostate biopsy will be randomly assigned to receive ice or standard care. The goal is …

This study tests whether men recovering from robotic prostate surgery can manage pain without automatically receiving opioid painkillers. Participants are counseled on pain management and then randomly assigned to either receive a standard opioid prescription plus other pain medi…

This study tests if a home-based exercise program can improve heart and lung fitness in men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy). The study will compare 60 men who exercise at home to those who receive only healthy living education…

This study looks at whether adding neuromuscular electrical stimulation to a physical activity program can help men on hormone therapy for prostate cancer keep their leg muscle strength. About 48 men who have been on hormone therapy for at least 26 weeks will take part. Researche…

This study tests a nationwide virtual clinic called SHAReClinic that provides education and counselling to help prostate cancer patients and their partners manage sexual health after treatment. About 575 people will take part, using online modules and surveys to track changes in …

This study checks if a few drops of blood on paper (dried blood spots) can accurately measure levels of certain prostate cancer drugs. About 100 patients on these medications will provide both standard blood samples and dried blood spots. If the new method works well, it could ma…

This study looks at the best times to send messages encouraging physical activity to older cancer survivors (age 65+) who have chronic pain. Researchers will track activity levels and pain ratings to see how messages affect movement and pain episodes. The goal is to learn how to …

This study is testing a web-based tool called CARE that gives cancer patients information about treatment costs, health insurance, and financial resources. About 430 adults with gynecologic, prostate, lung, or colorectal cancer will use the tool to see if it helps them feel more …

This study follows 130 men with metastatic prostate cancer who are receiving standard treatment with abiraterone and prednisone. Researchers want to see if a person's race or ethnicity affects how well the treatment works, by tracking PSA levels and genetic differences. The goal …

This study gathers medical records and scan results from 10,000 men with prostate cancer or at high risk. Researchers aim to find patterns in imaging that could lead to better diagnosis and treatment. No new drugs or procedures are tested; participants simply allow their existing…

This study looks at the genes and social factors that influence breast and prostate cancer in people of African descent. Researchers will collect blood and tumor samples from 1500 Black patients across the US, Africa, and the Caribbean. The goal is to find genetic changes and und…

This study tests a special MRI scan that uses a natural substance (hyperpolarized pyruvate) to see how active prostate cancer cells are. It involves 60 men with low- to intermediate-risk prostate cancer who are not receiving treatment but are being watched closely (active surveil…

This study looks at how to help veterans with advanced prostate cancer make informed choices about precision oncology tests, which use genetic information to guide treatment. Researchers will develop and test a decision-support tool to address gaps in understanding and reduce rac…

This study aims to see if a new telehealth program can safely reduce the number of in-person doctor visits for people with breast or prostate cancer. About 1,750 participants will be assigned to either enhanced telehealth or standard care. The goal is to make cancer care more con…

This study looks at how tilting patients head-down and inflating the belly with gas during robotic prostate cancer surgery affects pressure inside the head. Doctors will use an ultrasound on the eye to measure nerve swelling, a sign of brain pressure. The goal is to understand th…

This study is testing whether an AI program can automatically measure the amount of prostate cancer seen on special PET scans (PSMA PET-CT). The goal is to see if these AI measurements can predict how long patients will live or when the cancer might come back. The study will incl…

This study looks at 60 men with prostate cancer who had a high-risk genetic test (Decipher score >0.45). They will get a special PET scan (PSMA-PET) about 2 years after their first treatment to see if the cancer has spread. The goal is to learn how well the genetic test predicts …

This study collects blood samples from 1000 men with prostate cancer to look for genetic differences that may explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. The goal is…

This study is testing a program called MyCarePulse and ASCENT to help cancer patients overcome food-related challenges. About 100 adults recently diagnosed with certain cancers will either receive the program or standard care. Researchers will measure changes in food security, di…

This study looks at whether a special type of PET scan (PSMA-PET) and a blood test for tumor DNA can detect prostate cancer progression earlier than the standard PSA test. About 50 men with prostate cancer that has spread to a few spots will receive targeted radiation. Researcher…

This study involves 210 men with low-risk prostate cancer who are on active surveillance (monitoring instead of immediate treatment). Researchers will compare two imaging methods—micro-ultrasound and MRI—to see which better detects cancer progression during follow-up biopsies. Pa…

This study looks at whether artificial intelligence (AI) can help radiologists find prostate cancer on MRI scans. About 150 men aged 55-80 who are scheduled for a prostate biopsy will take part. Doctors will compare how well they detect cancer with and without AI assistance. The …

This study is testing a new way to screen for prostate cancer that is more likely to be life-threatening. It combines a man's genetic risk score with a special MRI scan to find higher-grade cancers. About 1,500 men aged 40-69 with no prior prostate cancer will get a PSA test, an …

This study follows up with people who previously took part in cancer vaccine studies using gene therapy. It does not give any new treatment. Instead, researchers check participants' health each year for 15 years to watch for any long-term side effects. The goal is to make sure th…

This study tests whether giving doctors AI-powered feedback on how they discuss prostate cancer risks helps patients make more informed decisions. About 259 men with early-stage prostate cancer and 24 doctors will take part. The goal is to see if this feedback reduces confusion a…

This study compares regular MRI scans to the usual monitoring for men with low-to-medium risk prostate cancer who choose active surveillance. Over 5 years, researchers will see if MRIs catch cancer progression earlier and reduce the need for biopsies and other tests. About 1,263 …

This study will collect and analyze tumor samples from 5,500 men with high-risk or advanced prostate cancer. Researchers will use genetic and imaging tests to find markers that predict how well different treatments work. The goal is to learn more about the disease, not to test a …

This study looks at how hormone treatments for prostate and breast cancer affect sleep quality. Researchers will monitor 60 patients using sleep tests, questionnaires, and activity trackers before treatment starts and again at 6 and 12 months. The goal is to understand if these t…

This study compares three types of prostate cancer surgery: robot-assisted, standard laparoscopic, and open surgery. It will enroll 2,000 men to see which method leads to better urinary and sexual function after the procedure. The goal is to provide clear evidence to help patient…

This study looks at whether a new analysis tool called TRAQinform Theranostics can help doctors make better treatment choices for men with metastatic prostate cancer. About 32 men who are starting a type of radiation therapy (177Lu-PSMA) will have their standard scans analyzed by…

This study aims to see if specially trained radiographers can make the same decisions as radiologists about prostate MRI scans. The goal is to reduce the need for contrast injections and extra scans, making the process faster and more efficient. The study will involve 1600 patien…

This study looks at whether a genetic test can help assess prostate cancer risk in men who either have the disease or are at high risk. Researchers will analyze DNA from 3,000 men to find rare and common genetic changes linked to prostate cancer. The goal is to see if this inform…

This study follows over 4,000 men with prostate cancer, some who carry rare gene mutations (like BRCA) and some who don't. Researchers will compare survival and cancer progression between the groups using medical records and tumor samples. The goal is to learn how these genes aff…

This study compares two ways to guide prostate biopsies using MRI: one where the doctor mentally fuses the MRI image with the ultrasound, and another using special software to overlay the images. The goal is to see which method finds more clinically significant prostate cancers. …

This study aims to validate a gene-based test that identifies oxygen-starved (hypoxic) tumours, which often resist standard radiotherapy. Researchers will collect tumour samples and MRI scans from 30 adults with bladder or prostate cancer undergoing radiotherapy. If successful, t…

This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA) can find cancer early after treatment. Researchers will follow about 100 people with different solid tumors, plus healthy volunteers, to see if the test helps predict when cancer comes back. …

This study is testing whether a new type of MRI scan can show if prostate cancer treatment is working after just 4 weeks. The scan looks at how cancer cells use sugar, which may change early when treatment is effective. About 32 men with high-risk prostate cancer will get the sca…

This study looks at whether a simple genetic test can help predict if a man has prostate cancer before he gets a biopsy. Researchers will compare the test results with actual biopsy findings in 1,000 men aged 40-69. The goal is to see if men at higher genetic risk are more likely…

This study looks at whether a digital app can help cancer patients get genetic testing directly from their oncologist, instead of visiting a separate genetics clinic. The goal is to see if this approach reduces patient distress and improves care. About 180 adults with breast, pro…

This study follows 106 men who have had surgery for prostate cancer to learn how long it takes to regain bladder control, sexual function, and overall health. Participants receive standard care resources and are monitored for up to 12 weeks. The goal is to better understand recov…

This study collects blood, urine, saliva, and tumor tissue from men with or suspected of having prostate cancer. Researchers will analyze these samples to learn how cell and gene changes cause prostate cancer to develop and grow. The goal is to find new ways to treat the disease.…

This study uses artificial intelligence to analyze MRI scans and tissue samples from 2,000 men with high-risk prostate cancer. The goal is to see if the AI can accurately predict whether the cancer has spread to lymph nodes before surgery. This is an observational study, meaning …

This study collects blood and leftover tissue samples from 9,600 adults with different types of cancer. Researchers will use these samples to develop and improve tests that detect cancer DNA in the blood, which may help monitor for cancer return or how well treatment is working. …

This study is creating a large database of medical information and blood samples from 350 adults receiving metabolic radiotherapy for thyroid cancer, prostate cancer, or neuroendocrine tumors. The goal is to provide researchers with valuable data to better understand these treatm…

This study follows 100 men with low- or very low-risk prostate cancer who choose active surveillance (monitoring instead of immediate treatment). Researchers will use remote symptom tracking and tissue samples to see how the disease progresses over 5 years. The goal is to learn w…

This study will analyze the complete DNA of tumors and normal cells from 882 breast and prostate cancer patients treated through Brazil's public health system. The goal is to create a detailed map of genetic changes linked to these cancers and build a national genomic database. P…

This study is developing and testing an educational tool to help men aged 65 and older with prostate cancer decide with their doctors whether to reduce the frequency of monitoring tests like biopsies or scans. The goal is to see if the tool is easy to use and helps patients feel …

This study aims to create an AI-powered early warning system to screen men aged 50 and older for prostate and bladder cancer. Researchers will test if this system can help find cancers sooner by coordinating care between community clinics, hospitals, and specialists. The goal is …

This study is watching how well different targeted treatments (like focused ultrasound, freezing, or laser) work for prostate cancer. Researchers will collect data from 200 men who are getting or have already received these treatments. The goal is to learn more about patient outc…

This study looks at how different Mediterranean-style diets affect the body's metabolism in men with early-stage prostate cancer who are not yet receiving treatment. Researchers will provide specific meals to 30 men and measure changes in their prostate tissue and blood. The goal…

This study looks at whether MRI scans can improve how doctors monitor low-risk prostate cancer in men who choose active surveillance (no immediate treatment). About 500 men will get regular MRIs alongside standard PSA tests and biopsies. The goal is to see if MRI can detect cance…

This study is testing a new blood test that looks for tiny bits of cancer DNA in the blood after prostate removal surgery. The goal is to see if this test can better predict if the cancer will come back early in men with high-risk prostate cancer. About 50 men will participate, a…

This study looks at whether a short educational session can increase the number of Black men with aggressive prostate cancer who get genetic testing. About 50 men will take part. The goal is to see if learning more about genetic testing helps them decide to get tested, which coul…

This study is creating and testing a simple, patient-friendly tool to help Black or African American men with metastatic prostate cancer understand genetic testing for their tumors. Researchers will interview participants to see if the tool is clear and helpful, and then measure …

This study enrolls 222 men with low- to intermediate-risk prostate cancer to see if combining MRI scans and a genetic test (GPS) helps them stick with active surveillance—monitoring the cancer instead of treating it right away. The goal is to find out whether one or both tests im…

This study is testing a new saliva-based DNA test called i4i PRODICT® that estimates a man's future risk of prostate cancer. Researchers want to see if men from Black, South Asian, and White backgrounds are willing to take the test and find it acceptable. The goal is to enroll 1,…

This study looks at why some prostate cancers stop responding to a type of targeted radiation therapy called PSMA radioligand therapy. Researchers will use scans and tumor biopsies from 125 people to measure how much radiation the tumors get and check for gene patterns linked to …

This study is not testing a new treatment. Instead, it will observe 400 men in Russia with a specific type of advanced prostate cancer to see what treatments they actually receive in routine care. Researchers will also look at tumor samples to study biomarkers. The goal is to und…

This study works with community leaders and genetic experts to create an online education program for African American cancer survivors. The goal is to help more people understand and choose genetic counseling and testing. About 85 participants from Detroit will try the program a…

This study is testing advanced MRI techniques to see if they can find prostate cancer more accurately than current scans. Researchers will compare different MRI models with detailed tissue analysis from 300 men scheduled for prostate removal. The goal is to improve diagnosis, not…

This study is not testing a new treatment. Instead, researchers will observe 400 men in Russia with aggressive, high-volume metastatic hormone-sensitive prostate cancer. They will track which treatments doctors choose and analyze blood samples for genetic mutations. The goal is t…

This study is looking for substances in urine that could help doctors predict how well prostate cancer treatments will work. Researchers will collect urine samples from 360 men with prostate cancer who are receiving standard treatments like surgery, radiation, chemotherapy, or ho…

This study checks if a new PET-CT scanner (RefleXion X1) can see prostate cancer tumors as well as the standard scanner does. About 25 men with prostate cancer who are already getting a standard PET scan will get an extra scan on the new machine. The goal is to see if the new sca…

This study looks at anxiety levels in men with low-risk prostate cancer who are on active surveillance (regular monitoring instead of immediate treatment) and their partners. Researchers will use questionnaires to measure anxiety and find out what factors might predict it. The go…

This study follows up to 2,000 men with prostate cancer who have specific gene mutations. Researchers want to learn how these gene changes affect the cancer's growth, spread, and response to treatment. Participants are contacted every 6 months and provide medical records, and som…

This study tests a new FDA-approved scanner that gives doctors a quick, detailed view of the prostate surface during surgery to find leftover cancer cells. The goal is to see if this method saves at least 20 minutes compared to the standard technique. About 78 men with intermedia…

This study is looking for markers in the blood that could help doctors predict how well prostate cancer treatments will work. Researchers will collect blood samples from 600 men at different stages of prostate cancer to measure certain immune cells and other substances. The goal …

This study tests whether visual decision-support tools help surgeons better discuss risks and benefits of surgery with patients who have prostate or kidney cancer. About 20 urologists and 200 patient visits will be studied, comparing conversations before and after the tools are i…

This study looks at how well African American and rural White men understand genetic information related to prostate cancer. Researchers will use an educational video and surveys to measure genetic literacy and knowledge. The goal is to help men make more informed decisions about…

This study collects blood and other samples from adults with cancer to learn how certain immune cells change before and after chemotherapy. Researchers will also analyze genes in the samples and link them to patient health details. The study does not provide any treatment, but pa…

This study looks at whether a special type of scan (PSMA PET/MRI) is better than a standard MRI at finding prostate cancer that comes back after a treatment called High-Intensity Focused Ultrasound (HIFU). About 60 men who have had HIFU for localized prostate cancer will get both…

This study is creating a huge collection of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand cancer causes, improve early detection, and develop person…

This study looks at whether a blood test can find tiny bits of tumor DNA in men with high-risk prostate cancer before they have surgery to remove the prostate. About 24 men will give blood samples, which will be tested with a highly sensitive method. The goal is to see if this te…

This study looks at how a new, more sensitive type of scan (PSMA PET) affects the anxiety, decision-making, and quality of life of 350 men with prostate cancer. Researchers will track patients' feelings and choices over a year using surveys and interviews. The goal is to understa…

This study looks at how urological diseases and treatments impact patients' jobs and daily lives. Researchers will survey 2,000 adults admitted to a hospital in Poland, focusing on those having major cancer surgeries or stone procedures. Participants will report their work status…

This study follows 64 men with localized prostate cancer who have keyhole surgery to remove the prostate. Researchers want to see how many patients have complications within the first 30 days after surgery. The goal is to better understand the risks of this outpatient procedure.

This study is for men with prostate cancer who are about to have radiation therapy or whose cancer has come back after earlier treatments. Researchers will use detailed MRI scans and biopsies to see how the tumor responds to radiation and why some cancers return. The goal is to b…

This study is building a collection of prostate tissue samples from people with inherited gene mutations that raise their risk for aggressive prostate cancer. Researchers will compare these samples to those from people without such mutations to learn how the disease develops and …

This study is a registry that will follow 5,000 men with prostate cancer that has come back or spread. The goal is to see what treatments doctors actually use and how the disease progresses over time. Participants are grouped by their cancer stage, from early PSA recurrence to ad…

This study compares two ways to check for prostate cancer in men with elevated PSA levels: the current approach of giving everyone an MRI, versus using a risk calculator to decide who needs an MRI and biopsy. The goal is to see if the risk calculator is just as good at finding da…

This study looks at whether a blood test (liquid biopsy) can detect prostate cancer cells as well as a special PET scan. Researchers will compare results from 80 patients to see if the blood test can show how far the cancer has spread. The goal is to find a less invasive way to m…

This study tests a special needle that uses light and sound to check prostate tissue during a standard biopsy. The goal is to see if the probe can reliably tell the difference between healthy and cancerous areas without taking extra tissue samples. About 50 men scheduled for a pr…

This study looks at tumor tissue from 150 Native American patients with prostate cancer. Researchers will analyze the genes in the tumors to see how they differ from those in Caucasian patients. The goal is to learn how these genetic differences might affect treatment choices and…

This study collects blood or cheek swab samples from people with cancer who are being treated at the National Cancer Institute. Researchers want to learn how genetic differences may affect how the body processes cancer treatments and whether certain genes are linked to side effec…

This study tests a community-based program to help underserved adults get screened for lung, breast, and prostate cancers. About 200 people who meet screening guidelines will be offered navigation support at community resource spots. The goal is to see if this approach increases …

This study is for people with advanced cancers who are taking targeted treatments for months or years. Researchers will interview 75 participants to understand their experiences and needs. The goal is to find better ways to support patients living with chronic cancer treatments.

This study gathers information from medical records of 534 people with metastatic prostate cancer around the world. Researchers want to see how well different treatments work in real life, including hormone therapy, a radioactive drug called Lutetium-177, and PARP inhibitors. The…

This study looks at how well newly diagnosed African-American men with early-stage prostate cancer understand what their doctor tells them about treatment. Researchers will give some patients an easy-to-read educational handout after their doctor visit and then interview them to …

This study tests a new imaging technique that uses sound waves created by radiation to see exactly where proton therapy is hitting inside the body. Researchers want to see if this method can help doctors deliver radiation more accurately to prostate tumors. About 30 men with pros…

This study is a large registry that will follow 8,000 cancer patients who receive radiation therapy guided by an MR-Linac, a machine that combines an MRI scanner with a radiation beam. The goal is to see if this technology helps people live longer, controls tumors better, and imp…

This study aims to see if watching a video before genetic testing helps people with certain cancers better understand their hereditary cancer risk. About 1020 adults with breast, ovarian, pancreatic, prostate, colorectal, renal, melanoma, or sarcoma cancers will take part. Resear…

This study aims to create and improve educational materials about genetic testing for people with breast, ovarian, prostate, pancreatic, or colorectal cancer. Researchers will interview 445 participants from diverse cultural and language backgrounds to get their feedback on the m…

This observational study will use SPECT imaging to measure how radiopharmaceutical therapies distribute in the body of 80 patients with advanced prostate or other cancers. The goal is to improve dosing calculations to make treatment safer and more effective. No new drugs are give…

This study looks at whether men with prostate cancer who get hot flashes from hormone therapy will wear a smartwatch to track their symptoms. For 4 weeks, 18 participants will log hot flashes on the watch and answer daily surveys. The goal is to see if the watch data matches the …

This study tests a new type of MRI scan that uses a special substance (hyperpolarized 13C-pyruvate) to see how prostate cancer cells use energy during and after radiation therapy. About 161 men with prostate cancer will get these scans before, during, and after treatment. The goa…

This study tests a new radioactive tracer called 64Cu-GRIP B, which attaches to a protein (granzyme B) made by immune cells. By using PET scans, doctors hope to see which tumors are responding to immunotherapy. The trial involves about 91 adults with advanced prostate, kidney, or…

This study is a large international registry that will follow at least 5,000 men with advanced prostate cancer from 15 countries. Researchers will collect detailed information on treatments, side effects, quality of life, and blood samples over five years. The goal is to understa…

This study looks at how cancer impacts the health and well-being of both patients and their family caregivers. Researchers will survey 240 Danish adults with breast, prostate, colorectal cancer, or lymphoma, along with their chosen caregivers. The goal is to identify families who…

This study compares two standard treatments for high-risk prostate cancer that hasn't spread: robot-assisted surgery and radiation therapy (often with hormone therapy). The goal is to see which approach better preserves quality of life, urinary and sexual function, and prevents t…

This study aims to describe the characteristics of prostate cancer in Algeria, including patient demographics, symptoms, diagnosis methods, and treatments. Researchers will collect information from 2,000 patients aged 19 and older with confirmed prostate cancer. The goal is to be…

This study looks at whether markers in the blood can tell doctors if a man's advanced prostate cancer will respond to hormone therapy. Researchers will collect blood samples from 120 men with metastatic castration-resistant prostate cancer during their standard treatment. They wi…

This study looks at men with high-risk prostate cancer that appears on only one side of the prostate. It compares removing lymph nodes from just that side versus both sides during robotic prostate surgery. The goal is to see if the less extensive surgery causes fewer complication…

This study creates a database to record how well freezing therapy (cryotherapy) works for men with early-stage prostate cancer that hasn't spread. Researchers will track 1,000 participants over time to see how long they live without their PSA levels rising. The goal is to better …

This study uses special PET/CT scans to see how advanced prostate cancer tumors become resistant to newer hormone therapies like enzalutamide or abiraterone. About 25 men with advanced prostate cancer who are starting or already on these treatments will get multiple scans over 9 …

This study looks at whether older men (70+) with prostate cancer who have been on hormone therapy for over three years can stop taking it. The idea is that their bodies may no longer produce testosterone, making the treatment unnecessary. Researchers will monitor testosterone lev…

This study looks at whether exposure to chlordecone, a pesticide banned in 1993 but still present in the environment, increases the risk of prostate cancer in men living in Martinique. Researchers will compare 3,600 men—some with prostate cancer and some without—measuring chlorde…

This study is testing a blood test that looks for tiny pieces of prostate cancer cells floating in the bloodstream, called circulating tumor cells (CTCs). The goal is to see if the number and type of these cells can tell doctors more about the cancer and how it responds to surger…

This study aims to improve how doctors predict prostate cancer progression and treatment response by combining advanced PSMA-PET scans with artificial intelligence. Researchers will collect scan data from 1,000 men with prostate cancer and use deep learning to discover imaging bi…

This study tests whether a smartphone app called Connect2Care can help African American men learn about prostate cancer and get a PSA screening test. About 266 men aged 45 to 69 from Oklahoma who haven't been screened recently will use either the Connect2Care app or a standard go…

This study follows 200 men with prostate cancer who are on active surveillance (monitoring instead of immediate treatment). It compares those with higher genetic risk to those with average risk to see how their cancer changes over time. The goal is to learn whether genetic factor…

This study aims to improve how doctors choose treatments for aggressive prostate cancer. Researchers will grow 3D mini-tumors from patient samples and test different therapies on them to see which works best. The goal is to find the most effective lab technique for predicting ind…

This study looks at whether giving cancer patients more personalized help (high-intensity navigation) makes them more likely to join a clinical trial compared to standard help (low-intensity navigation). About 90 adults with prostate or kidney cancer will take part. The goal is t…

This study aims to develop a computer model that uses MRI scans and patient information to predict whether a man has clinically significant prostate cancer (csPCa). Researchers will analyze data from 3,000 men who had an MRI and a prostate biopsy. The goal is to create a tool tha…

This study looks at a radioactive treatment called 177Lu-PSMA-617 for men with advanced prostate cancer that has spread. Researchers want to measure how much radiation the tumor and healthy organs receive, and see if that affects how well the treatment works or causes side effect…

This study follows 1,500 men newly diagnosed with prostate cancer to see how different treatments affect their quality of life and side effects over time. Researchers will collect health data and patient surveys to compare standard treatments like surgery and radiation with newer…

This study is for people already in the SYNERGY-201 trial for prostate cancer. It aims to find out if a biomarker called CXCR2 can predict who will benefit from the study drugs. Researchers will collect blood samples and optional tumor biopsies to track changes over time. The goa…

This study creates a large database of men with prostate cancer who choose prostate ablation (a minimally invasive treatment) instead of active surveillance or more aggressive therapies. Researchers will collect medical records from up to 3,000 participants to see how well ablati…

This study looks at whether patient navigators—people who guide and support patients through their care—can help more African American, Native American, and Hispanic patients complete radiation therapy for breast or prostate cancer. About 420 adults will take part. The goal is to…

This study looks at how standard radiation treatment for prostate cancer changes MRI and PET scans, and how those changes relate to tumor cells in the blood. About 144 men with prostate cancer will have scans and blood tests before, during, and up to 2.5 years after treatment. Th…

This study compares two advanced imaging techniques—PSMA PET/CT and MRI-RSI—against the current standard MRI for finding and outlining prostate tumors in 50 men with newly diagnosed, intermediate- to high-risk prostate cancer. The goal is to see if these newer methods improve tum…

This study is testing whether short educational videos can help Spanish-speaking Latinx patients with breast or prostate cancer better understand radiation therapy and feel more comfortable about joining clinical trials. About 194 participants will watch a video or read a brochur…

This study is testing whether a special PET/CT scan using a radioactive tracer called 18F-DCFPyL can find prostate cancer that has come back after initial treatment. About 350 men whose cancer has returned will be scanned and followed for up to 5 years. The goal is to see how wel…